Table 3 Overrepresented pathways, which could be affected by the differential expression of miR-26b, miR-200c, miR-203, miR-363-3p, and miR-1825

1.

p53 signaling pathway

<0,001

17

3

2.

Viral carcinogenesis

<0,001

33

4

3.

Small cell lung cancer

0,002

17

2

4.

Chronic myeloid leukemia

0,003

3

2

5.

Pathways in cancer

0,005

6

3

6.

Hepatitis B

0,009

1

1

7.

Prostate cancer

0,018

3

2

8.

ECM-receptor interaction

0,019

1

1

9.

Glycosaminoglycan biosynthesis - chondroitin sulfate

0,023

5

1

10.

Glioma

0,026

2

2

11.

Cell cycle

0,028

3

2

12.

ErbB signaling pathway

0,043

2

2

13.

Epstein-Barr virus infection

0,044

29

2